• Das Diabetes Magazin
  • Datenschutz
  • Impressum
  • Kontakt
Dienstag, April 13, 2021
Gartenfreunde
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
Keine Suchergebnisse
Alle Suchergebnisse einsehen
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes
Keine Suchergebnisse
Alle Suchergebnisse einsehen
Diabetes was nun?
Keine Suchergebnisse
Alle Suchergebnisse einsehen

Startseite » Allgemein » WSG and CANKADO’s EnReP predicts the benefits of anti-hormone therapy in breast cancer patients

WSG and CANKADO’s EnReP predicts the benefits of anti-hormone therapy in breast cancer patients

14. Dezember 2020
in Allgemein
Minuten Lesezeit2 min
WSG and CANKADO
Share on FacebookShare on Twitter

The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020

EnReP online tool predicts the benefits of anti-hormone therapy in breast cancer patients

Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy for hormone receptor-positive (HR+) / HER2-negative (HER2-) breast cancer patients.

The ADAPT study program evaluates options for patient-specific decision-making for breast cancer treatment based on modern biological markers. A central component here is the examination of the tumor’s response to a brief anti-hormone therapy prior to operation.

More than 5,000 patients from 80 breast centers in Germany participated in the ADAPT study. The groundbreaking results of the ADAPT study in early hormone-sensitive breast cancer are presented today for the WSG study group by Prof. Harbeck (Breast Center, University Hospital Munich).

The EnReP algorithm is based on the ADAPT study results and enables the prediction of patient’s endocrine therapy responses. EnReP thus supports therapy decisions in early hormone-sensitive breast cancer and is a milestone in therapy management.

The tool can be used as therapy decision support in around 40% of all breast cancer patients.

The West German Study Group (WSG) is a national research institution that focuses on the design, organization and implementation of clinical studies in the field of breast cancer. The goals of our studies are to optimize existing therapies in terms of effectiveness and tolerability, avoid unnecessary therapies and individualize breast cancer therapy.

The WSG is scientifically managed by Professor Dr. med. Ulrike Nitz (Breast Center Niederrhein, Mönchengladbach), Professor Dr. med. Nadia Harbeck (Breast Center, University Hospital Munich), PD Dr. med. Oleg Gluz (Breast Center Niederrhein, Mönchengladbach) and Prof. Dr. med. Sherko Kümmel (Senology Clinic / Interdisciplinary Breast Cancer Center of the Essen-Mitte Clinics).

The German e-Health platform CANKADO is constantly striving to improve patient care. CANKADO’s extensive know-how in providing dedicated e-Health support has enabled the successful implementation of the EnReP tool for the benefit of breast cancer patients.

CANKADO Service GmbH, headquartered in Germany, operates with over 50 employees with six offices in four countries and has project experience on all continents. CANKADO is the worldwide leading system for multi-lingual support of patients with chronic diseases in routine care and in clinical trials, also offering various digital health solutions in the areas of cancer, diabetes, cardiology, surgery, cell therapy, psychology, and nutrition.

  • 0933 Cologne

    https://partners.cankado.com/

  • 0933 Cologne

    https://www.linkedin.com/company/cankado/

Vorherige News

WSG und CANKADOs EnReP sagt den Nutzen von Antihormontherapie bei Brustkrebspatientinnen voraus

Nächste News

Die CANKADO Companion-APP: eine für Arzneimittel optimierte, digitale Anwendung für Pharmaunternehmen

Ähnliche Beiträge

"Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS" meldet sich mit neuem Format zurück
Allgemein

“Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS” meldet sich mit neuem Format zurück

22. März 2021
March4Obesity startet am Welt-Adipositas-Tag (4.3.2021)
Allgemein

March4Obesity startet am Welt-Adipositas-Tag (4.3.2021)

1. März 2021
Adipositas: wie das Gehirn den Stoffwechsel beeinflusst
Allgemein

Adipositas: wie das Gehirn den Stoffwechsel beeinflusst

14. Januar 2021
CANKADO
Allgemein

CANKADO’s Digital Health Solution Assists a New Clinical Trial, ADAPTlate

7. Januar 2021

Beliebte News

  • COVID-19: Das Wunder von Elgg oder 2 Covid Wellen im Altenheim ohne Tote

    COVID-19: Das Wunder von Elgg oder 2 Covid Wellen im Altenheim ohne Tote

    0 shares
    Share 0 Tweet 0
  • Covid-19: Antrag zur Empfehlung von Vitamin-D Einnahme im Bundestag abgelehnt.

    0 shares
    Share 0 Tweet 0
  • Rauchentwöhnung: So werden Sie rauchfrei

    0 shares
    Share 0 Tweet 0
  • Gemeinsame Mahlzeiten statt einsame Snacks

    0 shares
    Share 0 Tweet 0
  • SUBSTANTIAL EXPANSION OF CANKADO’s DIGITAL HEALTH SOLUTION

    0 shares
    Share 0 Tweet 0
  • Impressum
  • Datenschutz
  • Kontakt
© 2020 Diabetes-Wasnun.de
Keine Suchergebnisse
Alle Suchergebnisse einsehen
  • Diabetes Allgemein
  • Diabetes Typ 1
  • Diabetes Typ 2
  • Schwangerschaftsdiabetes